• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by BeiGene Ltd.

    3/10/25 6:08:15 AM ET
    $ONC
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ONC alert in real time by email
    DEFA14A 1 tm2420735d5_defa14a.htm DEFA14A

     

     

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

     

     

     

    SCHEDULE 14A
    (RULE 14a-101)
    SCHEDULE 14A INFORMATION

     

    Proxy Statement Pursuant to Section 14(a) of the
    Securities Exchange Act of 1934

     

     

     

    Filed by the Registrant x

     

    Filed by a Party other than the Registrant ¨

     

    Check the appropriate box:

     

    ¨  Preliminary Proxy Statement
       
    ¨  Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
       
    ¨  Definitive Proxy Statement
       
    x  Definitive Additional Materials
       
    ¨  Soliciting Material Pursuant to §240.14a-12

     

    BEIGENE, LTD.

    (Name of Registrant as Specified In Its Charter)

    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

     

    Payment of Filing Fee (Check the appropriate box):

     

    x  No fee required.
       
    ¨  Fee paid previously with preliminary materials.
       
    ¨  Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.

     

     

     

     

     

     

     

     

     

    Important Notice Regarding the Internet Availability of Proxy Materials for the Extraordinary General Meeting of Shareholders to be held at 8:30 a.m. Cayman Islands time on April 28, 2025

     

    This communication is not a form for voting and presents only an overview of the more complete proxy materials that are available to you on the Internet. We encourage you to access and review all of the important information contained in the proxy materials before voting.

     

    The proxy statement/prospectus and proxy card are available online at https://ir.beigene.com/filings-financials/shareholder-meeting-materials/.

     

    If you want to receive a paper or e-mail copy of these documents, you must request one. There is no charge to you for requesting a copy. Please make your request for a copy as instructed below on or before April 21, 2025 to facilitate timely delivery.

     

    Important information regarding the Internet availability of the Company’s proxy materials, instructions for accessing your proxy materials, voting instructions and instructions for requesting paper or e-mail copies of your proxy materials are provided on the reverse side of this Notice.

     

    Persons who hold shares indirectly through a brokerage firm, bank or other financial institution, including ADS holders, must contact their brokerage firm, bank or other financial institution for voting purposes, as voting by mail is not available to non-registered holders.

     

     

    To the Shareholders of BeiGene, Ltd.:

     

    The Extraordinary General Meeting of Shareholders (the “EGM”) of BeiGene, Ltd. (the “Company”) will be held on April 28, 2025, at 8:30 a.m. local time at the offices of Mourant Governance Services (Cayman) Limited, at 94 Solaris Avenue, Camana Bay, Grand Cayman KY1-1108, Cayman Islands to consider and vote on the following matters:

     

    1.      A special resolution to approve the Company’s de-registration in the Cayman Islands and the Company’s continuation in Switzerland (the “Continuation”), in accordance with our seventh amended and restated memorandum and articles of association (collectively, our “Articles”), Section 206 of the Companies Act (as amended) of the Cayman Islands and Article 161 of the Swiss Federal Code on Private International Law;

     

    2.     Subject to the approval of the Continuation, to consider and vote upon a special resolution to amend and restate the Company’s Articles in the form set forth in Exhibit A of the proxy statement/prospectus (the “Proposed Swiss Articles”), to be effective from the effective date of the Continuation; and

     

    3.     Subject to the approval of the Continuation and as required by Swiss law, to approve the election of Ernst & Young AG to serve as the Company’s statutory auditor (for Swiss legal purposes) until the Company’s first annual general meeting following the completion of the Continuation and provide related audit services and the authorization to the board of directors to fix the remuneration of Ernst & Young AG.

     

    Such other business as may properly come before the meeting or any adjournments or postponements thereof.

     

    The Board of Directors recommends you vote FOR all proposals.

     

     

     

     

    The Securities and Exchange Commission rules permit us to make our proxy materials available to our stockholders via the Internet.

     

    Materials for this meeting may be requested by one of the following methods:

     

    To view your proxy materials online, please go to https://ir.beigene.com/filings-financials/shareholder-meeting-materials/.
       
    To request proxy materials by telephone, please call +1 (877) 828-5568.
       
    To request proxy materials by e-email, please send an email to [email protected].

     

    The Extraordinary General Meeting of Shareholders (the “EGM”) of BeiGene, Ltd. (the “Company”) will be held on April 28, 2025, at 8:30 a.m. local time at the offices of Mourant Governance Services (Cayman) Limited, at 94 Solaris Avenue, Camana Bay, Grand Cayman KY1-1108, Cayman Islands. Only persons holding shares as of February 5, 2025 can attend and vote at the EGM. Instructions on how to attend and vote your shares are contained in the proxy statement/prospectus in the section titled “Information About The Extraordinary General Meeting and Voting.”

     

    The following proxy materials are available to you for review at: https://ir.beigene.com/ filings-financials/shareholder-meeting-materials/

    · Proxy Statement/Prospectus

    · Proxy Card

     

    Requesting a Paper Copy of the Proxy Materials

    By telephone: +1 (877) 828-5568

    By e-mail: [email protected]

     

     

     

     

    Get the next $ONC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ONC

    DatePrice TargetRatingAnalyst
    11/24/2025Buy
    Truist
    9/18/2025$385.00Overweight
    Barclays
    4/7/2025$312.00Outperform
    RBC Capital Mkts
    3/3/2025$207.00 → $320.00Neutral → Buy
    BofA Securities
    More analyst ratings

    $ONC
    SEC Filings

    View All

    BeOne Medicines Ltd. filed SEC Form 8-K: Termination of a Material Definitive Agreement

    8-K - BeOne Medicines Ltd. (0001651308) (Filer)

    12/19/25 6:01:09 AM ET
    $ONC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BeOne Medicines Ltd. filed SEC Form 8-K: Leadership Update

    8-K - BeOne Medicines Ltd. (0001651308) (Filer)

    12/18/25 6:02:54 AM ET
    $ONC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by BeOne Medicines Ltd.

    144 - BeOne Medicines Ltd. (0001651308) (Subject)

    12/15/25 4:32:14 PM ET
    $ONC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ONC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    BeOne Medicines Highlights Global Oncology Leadership at 44th Annual J.P. Morgan Healthcare Conference

    Company outlines foundational hematology leadership, multiple 2026 data catalysts, a unique global clinical development superhighway, and continued financial excellence BeOne Medicines Ltd. (NASDAQ:ONC, HKEX: 06160, SSE: 688235)), a global oncology company, will outline the pillars of its growing global oncology leadership during its presentation today at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco. John V. Oyler, Co-Founder, Chairman, and CEO at BeOne, will highlight the Company's transformative leadership in treating B-cell malignancies. The presentation will feature BRUKINSA®, the global leader among Bruton's tyrosine kinase (BTK) inhibitors, as well as foundat

    1/13/26 6:00:00 AM ET
    $ONC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ZIIHERA Plus TEVIMBRA and Chemotherapy: A Potential New Standard for First-Line HER2+ Advanced GEA

    Combination therapy showed compelling survival and disease control compared to current standard, regardless of PD-L1 status High GEA burden in Asia, where BeOne holds ZIIHERA rights, signals potential broad patient impact Results to be presented as a Late-Breaking Abstract Oral Presentation at ASCO GI on January 8, 2026 BeOne Medicines Ltd. (NASDAQ:ONC, HKEX: 06160, SSE: 688235)), a global oncology company, today announced full results from the Phase 3 HERIZON-GEA-01 trial evaluating ZIIHERA® (zanidatamab), a HER2-targeted bispecific antibody, in combination with chemotherapy, with and without PD-1 inhibitor TEVIMBRA® (tislelizumab), as a first-line treatment for HER2-positive (HER2+)

    1/6/26 1:30:00 PM ET
    $ONC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BeOne Medicines to Present at the 44th Annual J.P. Morgan Healthcare Conference

    BeOne Medicines Ltd. (NASDAQ:ONC, HKEX: 06160, SSE: 688235)), a global oncology company, today announced it will participate in the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026, with a presentation at 7:30 am PST. Live webcasts of these events can be accessed from the investors section of the Company's website at https://ir.beonemedicines.com, https://hkexir.beonemedicines.com, https://sseir.beonemedicines.com. Archived replays will be available on the Company's website. About BeOne Medicines BeOne Medicines is a global oncology company based in Switzerland that is discovering and developing innovative treatments that are more accessible to cancer patient

    12/23/25 6:01:00 AM ET
    $ONC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ONC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Truist initiated coverage on BeOne Medicines

    Truist initiated coverage of BeOne Medicines with a rating of Buy

    11/24/25 8:30:57 AM ET
    $ONC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Barclays initiated coverage on BeOne Medicines with a new price target

    Barclays initiated coverage of BeOne Medicines with a rating of Overweight and set a new price target of $385.00

    9/18/25 8:38:35 AM ET
    $ONC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    RBC Capital Mkts initiated coverage on BeiGene with a new price target

    RBC Capital Mkts initiated coverage of BeiGene with a rating of Outperform and set a new price target of $312.00

    4/7/25 8:43:36 AM ET
    $ONC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ONC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SVP, General Counsel Lee Chan Henry sold $580,197 worth of American Depositary Shares (1,660 units at $349.52) and exercised 1,660 units of American Depositary Shares at a strike of $191.40 (SEC Form 4)

    4 - BeOne Medicines Ltd. (0001651308) (Issuer)

    2/6/26 4:57:20 PM ET
    $ONC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SVP, General Counsel Lee Chan Henry exercised 664 units of American Depositary Shares at a strike of $191.56 and sold $220,289 worth of American Depositary Shares (664 units at $331.76) (SEC Form 4)

    4 - BeOne Medicines Ltd. (0001651308) (Issuer)

    1/9/26 5:15:55 PM ET
    $ONC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President, Global Head of R&D Wang Lai was granted 427,895 units of Ordinary Shares, increasing direct ownership by 42% to 1,451,424 units (SEC Form 4)

    4 - BeOne Medicines Ltd. (0001651308) (Issuer)

    1/5/26 5:12:01 PM ET
    $ONC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ONC
    Leadership Updates

    Live Leadership Updates

    View All

    The Institute for Follicular Lymphoma Innovation (IFLI) Appoints Innovative Leaders Mehrdad Mobasher, M.D., M.P.H., and Carol O'Hear, M.D., Ph.D., as Executive Partners

    DIAMOND BAR, Calif., Oct. 21, 2025 /PRNewswire/ -- The Institute for Follicular Lymphoma Innovation (IFLI), a global, non-profit, private foundation dedicated to accelerating the development of innovative treatment options for patients with follicular lymphoma (FL)., today announced the appointments of Mehrdad Mobasher, M.D., M.P.H., and Carol O'Hear, M.D., Ph.D., as Executive Partners. "I believe Carol and Mehrdad will be exceptional partners to the IFLI team and portfolio as they bring decades of strategic leadership and drug development expertise," said David McCullagh, Man

    10/21/25 8:05:00 AM ET
    $CRVS
    $DNA
    $EXEL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    $ONC
    Financials

    Live finance-specific insights

    View All

    BeOne Medicines Announces Third Quarter 2025 Financial Results and Business Updates

    Third quarter total revenues increased 41% to $1.4 billion versus third quarter 2024 Global BRUKINSA® (zanubrutinib) revenues increased 51% to $1.0 billion versus third quarter 2024 Diluted GAAP Earnings per American Depository Share (ADS) of $1.09, non-GAAP diluted Earnings per ADS of $2.65 47 abstracts accepted at American Society of Hematology (ASH) Annual Meeting BeOne Medicines Ltd. (NASDAQ:ONC, HKEX: 06160, SSE: 688235)), a global oncology company, today announced financial results and corporate updates from the third quarter of 2025. "These strong financial results reinforce our position as a global oncology leader with exceptional topline growth and a strong balance sheet,

    11/6/25 6:00:00 AM ET
    $ONC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BeOne Medicines Announces Second Quarter 2025 Financial Results and Business Updates

    Second quarter total revenues increased 42% to $1.3 billion versus second quarter 2024 Global BRUKINSA revenues increased 49% to $950 million versus second quarter 2024 Reported diluted GAAP Earnings per American Depositary Share (ADS) of $0.84, non-GAAP diluted Earnings per ADS of $2.25 Anticipate 20+ milestones in next 18 months across hematology and solid tumor pipeline BeOne Medicines Ltd. (NASDAQ:ONC, HKEX: 06160, SSE: 688235)), a global oncology company, today announced financial results and corporate updates from the second quarter of 2025. "Our strong second quarter performance reinforces our trajectory as a global oncology powerhouse and underscores our proven abilit

    8/6/25 6:00:00 AM ET
    $ONC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BeiGene Announces First Quarter 2025 Financial Results and Business Updates

    First quarter 2025 total revenues increased 49% to $1.1 billion with BRUKINSA® (zanubrutinib) global sales increasing 62% to $792 million on strong demand growth versus first quarter 2024 Achieved GAAP profitability and significantly improved operating cash flow Advanced late-stage hematology and solid tumor pipelines with plan to host Investor R&D Day on June 26 Secured shareholder approval to rename the Company to BeOne Medicines Ltd. and redomicile to Switzerland BeiGene, Ltd. (NASDAQ:ONC, HKEX: 06160, SSE: 688235)), a global oncology company that will change its name to BeOne Medicines, Ltd., today announced financial results and corporate updates from the first quarter 2025.

    5/7/25 6:00:00 AM ET
    $ONC
    Biotechnology: Pharmaceutical Preparations
    Health Care